2023-06-012024-05-312024-05-31false08082880MEDICINES DIRECT LIMITED2025-02-14falseiso4217:GBPxbrli:pure080828802023-06-01080828802024-05-31080828802023-06-012024-05-31080828802022-06-01080828802023-05-31080828802022-06-012023-05-3108082880bus:SmallEntities2023-06-012024-05-3108082880bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3108082880bus:FullAccounts2023-06-012024-05-3108082880bus:PrivateLimitedCompanyLtd2023-06-012024-05-3108082880core:WithinOneYear2024-05-3108082880core:AfterOneYear2024-05-3108082880core:WithinOneYear2023-05-3108082880core:AfterOneYear2023-05-3108082880core:ShareCapital2024-05-3108082880core:SharePremium2024-05-3108082880core:RevaluationReserve2024-05-3108082880core:OtherReservesSubtotal2024-05-3108082880core:RetainedEarningsAccumulatedLosses2024-05-3108082880core:ShareCapital2023-05-3108082880core:SharePremium2023-05-3108082880core:RevaluationReserve2023-05-3108082880core:OtherReservesSubtotal2023-05-3108082880core:RetainedEarningsAccumulatedLosses2023-05-3108082880core:LandBuildings2024-05-3108082880core:PlantMachinery2024-05-3108082880core:Vehicles2024-05-3108082880core:FurnitureFittings2024-05-3108082880core:OfficeEquipment2024-05-3108082880core:NetGoodwill2024-05-3108082880core:IntangibleAssetsOtherThanGoodwill2024-05-3108082880core:ListedExchangeTraded2024-05-3108082880core:UnlistedNon-exchangeTraded2024-05-3108082880core:LandBuildings2023-05-3108082880core:PlantMachinery2023-05-3108082880core:Vehicles2023-05-3108082880core:FurnitureFittings2023-05-3108082880core:OfficeEquipment2023-05-3108082880core:NetGoodwill2023-05-3108082880core:IntangibleAssetsOtherThanGoodwill2023-05-3108082880core:ListedExchangeTraded2023-05-3108082880core:UnlistedNon-exchangeTraded2023-05-3108082880core:LandBuildings2023-06-012024-05-3108082880core:PlantMachinery2023-06-012024-05-3108082880core:Vehicles2023-06-012024-05-3108082880core:FurnitureFittings2023-06-012024-05-3108082880core:OfficeEquipment2023-06-012024-05-3108082880core:NetGoodwill2023-06-012024-05-3108082880core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3108082880core:ListedExchangeTraded2023-06-012024-05-3108082880core:UnlistedNon-exchangeTraded2023-06-012024-05-3108082880core:MoreThanFiveYears2023-06-012024-05-3108082880core:Non-currentFinancialInstruments2024-05-3108082880core:Non-currentFinancialInstruments2023-05-3108082880dpl:CostSales2023-06-012024-05-3108082880dpl:DistributionCosts2023-06-012024-05-3108082880core:LandBuildings2023-06-012024-05-3108082880core:PlantMachinery2023-06-012024-05-3108082880core:Vehicles2023-06-012024-05-3108082880core:FurnitureFittings2023-06-012024-05-3108082880core:OfficeEquipment2023-06-012024-05-3108082880dpl:AdministrativeExpenses2023-06-012024-05-3108082880core:NetGoodwill2023-06-012024-05-3108082880core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3108082880dpl:GroupUndertakings2023-06-012024-05-3108082880dpl:ParticipatingInterests2023-06-012024-05-3108082880dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3108082880core:ListedExchangeTraded2023-06-012024-05-3108082880dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3108082880core:UnlistedNon-exchangeTraded2023-06-012024-05-3108082880dpl:CostSales2022-06-012023-05-3108082880dpl:DistributionCosts2022-06-012023-05-3108082880core:LandBuildings2022-06-012023-05-3108082880core:PlantMachinery2022-06-012023-05-3108082880core:Vehicles2022-06-012023-05-3108082880core:FurnitureFittings2022-06-012023-05-3108082880core:OfficeEquipment2022-06-012023-05-3108082880dpl:AdministrativeExpenses2022-06-012023-05-3108082880core:NetGoodwill2022-06-012023-05-3108082880core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3108082880dpl:GroupUndertakings2022-06-012023-05-3108082880dpl:ParticipatingInterests2022-06-012023-05-3108082880dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3108082880core:ListedExchangeTraded2022-06-012023-05-3108082880dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3108082880core:UnlistedNon-exchangeTraded2022-06-012023-05-3108082880core:NetGoodwill2024-05-3108082880core:IntangibleAssetsOtherThanGoodwill2024-05-3108082880core:LandBuildings2024-05-3108082880core:PlantMachinery2024-05-3108082880core:Vehicles2024-05-3108082880core:FurnitureFittings2024-05-3108082880core:OfficeEquipment2024-05-3108082880core:AfterOneYear2024-05-3108082880core:WithinOneYear2024-05-3108082880core:ListedExchangeTraded2024-05-3108082880core:UnlistedNon-exchangeTraded2024-05-3108082880core:ShareCapital2024-05-3108082880core:SharePremium2024-05-3108082880core:RevaluationReserve2024-05-3108082880core:OtherReservesSubtotal2024-05-3108082880core:RetainedEarningsAccumulatedLosses2024-05-3108082880core:NetGoodwill2023-05-3108082880core:IntangibleAssetsOtherThanGoodwill2023-05-3108082880core:LandBuildings2023-05-3108082880core:PlantMachinery2023-05-3108082880core:Vehicles2023-05-3108082880core:FurnitureFittings2023-05-3108082880core:OfficeEquipment2023-05-3108082880core:AfterOneYear2023-05-3108082880core:WithinOneYear2023-05-3108082880core:ListedExchangeTraded2023-05-3108082880core:UnlistedNon-exchangeTraded2023-05-3108082880core:ShareCapital2023-05-3108082880core:SharePremium2023-05-3108082880core:RevaluationReserve2023-05-3108082880core:OtherReservesSubtotal2023-05-3108082880core:RetainedEarningsAccumulatedLosses2023-05-3108082880core:NetGoodwill2022-06-0108082880core:IntangibleAssetsOtherThanGoodwill2022-06-0108082880core:LandBuildings2022-06-0108082880core:PlantMachinery2022-06-0108082880core:Vehicles2022-06-0108082880core:FurnitureFittings2022-06-0108082880core:OfficeEquipment2022-06-0108082880core:AfterOneYear2022-06-0108082880core:WithinOneYear2022-06-0108082880core:ListedExchangeTraded2022-06-0108082880core:UnlistedNon-exchangeTraded2022-06-0108082880core:ShareCapital2022-06-0108082880core:SharePremium2022-06-0108082880core:RevaluationReserve2022-06-0108082880core:OtherReservesSubtotal2022-06-0108082880core:RetainedEarningsAccumulatedLosses2022-06-0108082880core:AfterOneYear2023-06-012024-05-3108082880core:WithinOneYear2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3108082880core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3108082880core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3108082880core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3108082880core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3108082880core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3108082880bus:Director12023-06-012024-05-3108082880bus:Director22023-06-012024-05-31

MEDICINES DIRECT LIMITED

Registered Number
08082880
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

MEDICINES DIRECT LIMITED
Company Information
for the year from 1 June 2023 to 31 May 2024

Directors

Mr A K Sharma
Mrs G Sharma

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

08082880 (England and Wales)
MEDICINES DIRECT LIMITED
Balance Sheet as at
31 May 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Investments431,00025,000
Investment property31,162,9721,162,972
1,193,9721,187,972
Current assets
Debtors5461,861413,915
Cash at bank and on hand8,7776,944
470,638420,859
Creditors amounts falling due within one year6(1,538,058)(1,479,141)
Net current assets (liabilities)(1,067,420)(1,058,282)
Total assets less current liabilities126,552129,690
Creditors amounts falling due after one year7(123,142)(128,014)
Net assets3,4101,676
Capital and reserves
Called up share capital22
Profit and loss account3,4081,674
Shareholders' funds3,4101,676
The financial statements were approved and authorised for issue by the Board of Directors on 14 February 2025, and are signed on its behalf by:
Mr A K Sharma
Director
Registered Company No. 08082880
MEDICINES DIRECT LIMITED
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from rendering of services
Turnover is measured from the open market value of rental income charged on the investment Properties.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Investments
Investments are listed at cost.
Investment property
Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised as cost, which includes the purchase cost and any directly attributable expenditure.
2.Average number of employees

20242023
Average number of employees during the year00
3.Investment property

£
Fair value at 01 June 231,162,972
At 31 May 241,162,972
4.Fixed asset investments

Other investments1

Total

££
Cost or valuation
At 01 June 2325,00025,000
Additions6,0006,000
At 31 May 2431,00031,000
Net book value
At 31 May 2431,00031,000
At 31 May 2325,00025,000

Notes

1Other investments other than loans
5.Debtors: amounts due within one year

2024

2023

££
Other debtors459,876413,491
Prepayments and accrued income1,985424
Total461,861413,915
6.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables51,15048,000
Bank borrowings and overdrafts5,7645,546
Taxation and social security1,2583,058
Other creditors1,479,8861,422,537
Total1,538,0581,479,141
7.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts123,142128,014
Total123,142128,014
8.Related party transactions
Other creditors includes the following; Medicines 4U Ltd £1,446,801 (2023: £1,386,417), Online Prescriptions Ltd £32,000 (2023: £32,000), Medicines R Us Ltd Nil (2023: £1,500), There is common directorship in these companies. Director's current account credit balance of £1,084 (2023: £2,620) relates to A K Sharma.